1. Signaling Pathways
  2. Apoptosis
  3. Bcl-2 Family

Bcl-2 Family (Bcl-2蛋白家族)

Bcl-2 is a family of evolutionarily related proteins. These proteins govern mitochondrial outer membrane permeabilization (MOMP) and can be either pro-apoptotic (Bax, Bad, Bak and Bok among others) or anti-apoptotic (including Bcl-2 proper, Bcl-xL, and Bcl-w, among an assortment of others). There are a total of 25 genes in the Bcl-2 family known to date. Human genes encoding proteins that belong to this family include: Bak1, Bax, Bal-2, Bok, Mcl-1.

目录号 产品名 作用方式 纯度
  • HY-15531
    Venetoclax

    维奈妥拉

    Inhibitor 99.95%
    Venetoclax (ABT-199; GDC-0199) 是一种高效,有选择性和口服有效的 Bcl-2 抑制剂,Ki 小于0.01 nM。Venetoclax 可以诱导自噬 (autophagy) 作用。
  • HY-10087
    Navitoclax

    生根粉263

    Inhibitor 99.97%
    Navitoclax (ABT-263) 是一种口服有效的 Bcl-2 抑制剂,可与 Bcl-xLBcl-2Bcl-w 等多种 Bcl-2 家族蛋白结合,Ki 值小于 1 nM。
  • HY-100741
    S63845 Inhibitor 99.94%
    S63845 是一种有效的选择性骨髓细胞白血病 1 (MCL1) 抑制剂,结合人 MCL1Kd 值为 0.19 nM。
  • HY-50907
    ABT-737 Inhibitor 99.96%
    ABT-737 是一种 BH3 模拟物,是一种有效的 Bcl-2Bcl-xLBcl-w 抑制剂,EC50 分别为 30.3 nM、78.7 nM 和 197.8 nM。ABT-737 诱导 BCL-2/BAX 复合物的破坏和 BAK 依赖性但不依赖 BIM 的内在凋亡途径激活。ABT-737 诱导自噬,并且具有用于急性髓系白血病 (AML) 研究的潜力。
  • HY-19741
    A-1331852 Inhibitor 99.65%
    A-1331852是具有口服活性的BCL-XL选择性抑制剂,Ki值小于10 pM。
  • HY-N0674B
    Dehydrocorydaline (hydroxyl) Modulator 99.77%
    Dehydrocorydaline hydroxyl (13-Methylpalmatine) 是一种生物碱。Dehydrocorydaline hydroxyl 调节 BaxBcl-2 蛋白表达;激活 caspase-7caspase-8,并使 PARP 失活。Dehydrocorydaline hydroxyl 能增强 p38 MAPK 活化,具有抗炎、抗癌等功效。Dehydrocorydaline hydroxyl 具有强大的抗疟疾作用,并具低细胞毒性 (细胞生存力> 90%), P. falciparum 3D7 strain (IC50=38 nM)。
  • HY-156620
    Lacutoclax Inhibitor
    Lacutoclax 是一种具有抗肿瘤活性的 Bcl-2 抑制剂。
  • HY-149086
    BPA-B9 Inhibitor
    BPA-B9 是一种 RXRα 配体和拮抗剂,靶向 pRXRα-PLK1 相互作用。BPA-B9 具有出色的 RXRα 结合亲和力 (KD=39.29 ± 1.12 nM)。 BPA-B9 通过诱导有丝分裂停滞和细胞凋亡 (apoptosis) 来抑制癌细胞的增殖。
  • HY-101533
    AZD-5991 Inhibitor 99.50%
    AZD-5991 是一种有效的选择性 Mcl-1 抑制剂,FRET 实验检测的 IC50 为 0.7 nM, SPR 实验检测的 Kd 为 0.17 nM。
  • HY-114855
    BT2 Inhibitor 99.56%
    BT2 是 BCKDC 激酶 (BDK) 抑制剂,IC50 值为 3.19 μM。BT2 与 BDK 的结合会触发支链 α-酮酸脱氢酶复合物 (BCKDC) 的 N 末端结构域的螺旋运动,从而导致 BDK 与 BCKDC 分离。BT2 (compound 4) 也是一种有效的选择性的 Mcl-1 抑制剂,Ki 值为 59 μM。
  • HY-19725
    A-1155463 Inhibitor 99.60%
    A-1155463是高效选择性的 BCL-XL 抑制剂,在Molt-4细胞中的EC50值为70 nM。
  • HY-112218
    MIK665 Inhibitor 99.72%
    MIK665 (S-64315) ,源于 S63845,是一种髓系细胞白血病序列1 (MCL1) 抑制剂,对 MCL1 的 IC50 为 1.81 nM。
  • HY-10969
    Obatoclax Mesylate

    奥巴克拉甲磺酸盐

    Inhibitor 99.74%
    Obatoclax Mesylate (GX15-070 Mesylate) 是 BH3 模拟物,是泛 BCL-2 家族蛋白抑制剂,对 BCL-2Ki 值为 220 nM。Obatoclax Mesylate 诱导自噬 (autophagy) 依赖性细胞死亡,并靶向细胞周期蛋白 D1 进行蛋白酶体降解。Obatoclax Mesylate 具有抗癌和广谱抗寄生虫 (antiparasitic) 活性。
  • HY-15607A
    WEHI-539 hydrochloride Inhibitor 98.31%
    WEHI-539 hydrochloride 是一种选择性的 Bcl-XL 抑制剂,IC50 为 1.1 nM。
  • HY-108705
    BI-3802 Inhibitor 99.43%
    BI-3802 是一种高效的 BCL6 降解剂,能够抑制 BCL6 的Bric-à-brac (BTB) 结构域,IC50 值 ≤3 nM。BI-3802 可诱导 BCL6 蛋白聚集,并促进 E3 连接酶 SIAH1 介导的蛋白降解。BI-3802 具有抗肿瘤活性。
  • HY-101565
    Tapotoclax Inhibitor 99.80%
    Tapotoclax (AMG-176) 是一种有效的、有口服活性的、骨髓细胞因子 1 (MCL-1) 的选择性抑制剂,其 Ki 值为 0.13 nM。
  • HY-112416
    AZD4320 Inhibitor 99.68%
    AZD4320 是 BH-3 的新型类似物,有效的 BCL2/BCLxL 的双重抑制剂。AZD4320 对于 KPUM-MS3,KPUM-UH1,和 STR-428 细胞系的 IC50 分别为 26 nM,17 nM,和 170 nM。
  • HY-N0674
    Dehydrocorydaline

    脱氢紫堇碱

    Modulator 99.77%
    Dehydrocorydaline (13-Methylpalmatine) 是一种生物碱。Dehydrocorydaline 调节 BaxBcl-2 蛋白表达;激活 caspase-7caspase-8,并使 PARP 失活。Dehydrocorydaline 能增强 p38 MAPK 活化,具有抗炎、抗癌等功效。Dehydrocorydaline 具有强大的抗疟疾作用,并具低细胞毒性 (细胞生存力> 90%), P. falciparum 3D7 strain (IC50=38 nM)。
  • HY-12048
    Chelerythrine chloride

    盐酸白屈菜红碱

    Inhibitor 98.86%
    Chelerythrine chloride 是一种有效,可渗透细胞的蛋白酶 C (protein kinase C) 抑制剂,能够抑制 PKC 活性,IC50 值为 660 nM。Chelerythrine chloride 抑制 Bcl-XL-Bak BH3 肽结合,IC50 为 1.5 μM,并从 Bcl-XL 取代了 Bax。Chelerythrine chloride 诱导细胞凋亡 (apoptosis) 和自噬 (autophagy)。
  • HY-12468
    A-1210477 Inhibitor 99.40%
    A-1210477 是一种有效,选择性的 MCL-1 抑制剂,Ki 值为 0.45 nM。A-1210477 特异性结合 MCL-1,并以 MCL-1 依赖性方式促进癌细胞凋亡 (apoptosis)。
目录号 产品名 / 同用名 应用 反应物种

Bcl-2 family members have been grouped into three classes. The anti-apoptotic subfamily contains the Bcl-2, Bcl-XL, Bcl-w, Mcl-1, Bfl1/A-1, and Bcl-B proteins, which suppress apoptosis and contain all four Bcl-2 homology domains, designated BH1-4. The pro-apoptotic subfamily contain BH1-3 domains, such as Bax, Bak, and Bok. A third class of BH3 only proteins Bad, Bid, Bim, Noxa and Puma have a conserved BH3 domain that can bind and regulate the anti-apoptotic BCL-2 proteins to promote apoptosis [1].


The intrinsic pathway is initiated by various signals, principally extracellular stimuli. BH3-only proteins (Bim, Bid, Bad, Noxa, Puma) engage with anti-apoptotic Bcl-2 family proteins to relieve their inhibition of Bax and Bak to activate them. Next, Bax and Bak are oligomerized and activated, leading to mitochondrial outer membrane permeabilization. Once mitochondrial membranes are permeabilized, cytochrome c and/or Smac/DIABLO is released into the cytoplasm, wherein they combine with an adaptor molecule, Apaf-1, and an inactive initiator Caspase, Pro-caspase 9, within a multiprotein complex called the apoptosome. Smac/DIABLO inhibits IAPs to activate Caspase 9. Caspase 9 activates Caspase 3, which is the initiation step for the cascade of Caspase activation. The extrinsic pathway can be activated by cell surface receptors, such as Fas and TNF Receptor, subsequently activating Caspase 8, and leads to Caspase 3 activation and cell demolition. Caspases in turn cleave a series of substrates, activate DNases and orchestrate the demolition of the cell. Bcl-2 family proteins are also found on the endoplasmic reticulum and the perinuclear membrane in hematopoietic cells, but they are predominantly localized to mitochondria [2]

 

Reference:
[1]. Cotter TG, et al. Apoptosis and cancer: the genesis of a research field. Nat Rev Cancer. 2009 Jul;9(7):501-7.

[2]. Kang MH, et al. Bcl-2 inhibitors: targeting mitochondrial apoptotic pathways in cancer therapy. Clin Cancer Res. 2009 Feb 15;15(4):1126-32.

Your Search Returned No Results.

Sorry. There is currently no product that acts on isoform together.

Please try each isoform separately.